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ABSTRACT
It is increasingly perceived that gut hostemicrobial
interactions are important elements in the pathogenesis
of functional gastrointestinal disorders (FGID). The most
convincing evidence to date is the finding that functional
dyspepsia and irritable bowel syndrome (IBS) may
develop in predisposed individuals following a bout of
infectious gastroenteritis. There has been a great deal of
interest in the potential clinical and therapeutic
implications of small intestinal bacterial overgrowth in
IBS. However, this theory has generated much debate
because the evidence is largely based on breath tests
which have not been validated. The introduction of
culture-independent molecular techniques provides
a major advancement in our understanding of the
microbial community in FGID. Results from 16S rRNA-
based microbiota profiling approaches demonstrate both
quantitative and qualitative changes of mucosal and
faecal gut microbiota, particularly in IBS. Investigators
are also starting to measure hostemicrobial interactions
in IBS. The current working hypothesis is that abnormal
microbiota activate mucosal innate immune responses
which increase epithelial permeability, activate
nociceptive sensory pathways and dysregulate the
enteric nervous system. While we await important
insights in this field, the microbiota is already
a therapeutic target. Existing controlled trials of dietary
manipulation, prebiotics, probiotics, synbiotics and
non-absorbable antibiotics are promising, although most
are limited by suboptimal design and small sample size.
In this article, the authors provide a critical review of
current hypotheses regarding the pathogenetic
involvement of microbiota in FGID and evaluate the
results of microbiota-directed interventions. The authors
also provide clinical guidance on modulation of gut
microbiota in IBS.
INTRODUCTION
Functional gastrointestinal disorders (FGIDs) are
deﬁned by symptom-based diagnostic criteria that
combine chronic or recurrent symptoms attribut-
able to the GI tract in the absence of other patho-
logically-based disorders.1 The FGIDs are classiﬁed
into six major categories for adults: oesophageal,
gastroduodenal, bowel, functional abdominal pain
syndrome, biliary and anorectal. Of these, the
functional bowel disorders (FBD) constitute one of
the most common reasons for seeking healthcare,2
and they are associated with poor health-related
quality of life3e5 and substantial costs to society.6e9
The pathophysiological mechanisms underlying
these disorders are incompletely known, but
abnormal gastrointestinal (GI) motility, visceral
hypersensitivity, altered brainegut function, low-
grade inﬂammation, psychosocial disturbance and
intestinal microbes may contribute.10e12
The human body is inhabited by a complex
community of microbes, collectively referred to as
microbiota.13 It is estimated that the human
microbiota contains 1014 cells, which outnumber
the human cells in our bodies by a factor of ten.14 A
vast majority of these are found in the GI tract,
with a continuum from 101e103 bacteria per gram
of content in the stomach and duodenum to
1011e1012 cells per gram in the colon.15 Moreover,
the microbial composition differs between these
sites,16 and there are also signiﬁcant differences
between the microbiota present in the gut lumen
and the microbiota attached to and embedded in
the mucus layer of the GI tract.17 The microbiota is
taxonomically classiﬁed via the traditional biolog-
ical nomenclature (phylumdclassdorderd
familydgenusdspecies) and currently more than
50 bacterial phyla have been described, of which 10
inhabit the colon and three predominate: the
Firmicutes, Bacteroidetes and the Actinobacteria;
other sites display a different microbial composi-
tion.18 19 A challenge for researchers and clinicians
is that most of the microbial diversity in the
human GI tract is not currently represented by
available cultured species,20 but during recent years,
the use of culture-independent techniques to study
the gut microbiota has increased the understanding
of the role of gut microbiota in health and disease.14
Several lines of evidence indicate that bacteria
may be involved in the pathogenesis and patho-
physiology of FBD, through the metabolic capacity
of the luminal microbiota, and the potential of the
mucosa-associated microbiota to inﬂuence the host
via immuneemicrobial interactions.21 For instance,
many subjects with irritable bowel syndrome (IBS)
report symptom onset following an enteric infec-
tion.22 There are also studies reporting positive
effects of treatments directed at gut microbiota in
patients with FBD.23 24 Moreover, small intestinal
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bacterial overgrowth (SIBO)25 and altered intestinal
microbiota26 are implicated in subgroups of FBD
patients. However, the clinical relevance of these
ﬁndings remains unclear and, therefore, we sought
to critically review the existing literature on the
role of intestinal microbiota in FBD, focusing
predominantly on IBS, and to provide recommen-
dations for how to implement the current knowl-
edge into clinical practice and to guide future
research.
This manuscript is a synthesis of the endeavour
of the Rome Foundation Committee Report. More
indepth description of the work produced by this
team is provided as online supplementary material.
CURRENT KNOWLEDGE OF THE MICROBIOTA
A relationship, often termed symbiosis, has devel-
oped between the host and the intestinal micro-
biota over millions of years. Host genetic and
immune as well as environmental factors inﬂuence
intestinal microbiota composition which in turn
shape host immunity and physiology within and
beyond the gut (ﬁgure 1). Recent human studies
demonstrate a hitherto unimagined complexity of
the human gut microbiota with hundreds of
phylotypes, of which 80% remain uncultured.19 Of
the 10 bacterial phyla detected in the gut the
Firmicutes, Bacteroidetes and Actinobacteria
predominate, of which the Firmicutes is the most
dominant and diverse phylum in the GI tract.
Facultative anaerobes account for <0.1% of the
total bacteria detected in faecal samples. A recent
paper suggested that the human GI tract micro-
biota can be divided into three robust clusters called
enterotypes formed by groups of species that
jointly contribute to their respective preferred
community composition.27 Remarkably, these
enterotypes do not vary by patient characteristics,
such as nation, gender, age or body mass index,
although these ﬁndings are based on relatively
small numbers of subjects. While most studies used
faecal material, this does differ somewhat from the
bacteria adherent to the mucosa, which are likely to
interact most strongly with the host.28
Babies are born with sterile intestines but are
rapidly colonised by bacteria from their immediate
environment, most importantly their mother ’s
vagina and gut.29 Early colonisers of the neonatal
gut are mainly aerobes (such as staphylococci,
streptococci and enterobacteria), while late colo-
nisers are strict anaerobes (such as eubacteria and
clostridia) as the total microbiota become more
complex, more stable and converge to a common
pattern.30 31 Themicrobiota continue to evolve until
adulthoodwith a gradual increase in Bacteroides spp.,
a decline in Lactobacillus spp. after the age of ﬁve and
a decline in Biﬁdobacterium spp. in late teenage.32
Changes also occur in extreme old age when
Bacteroides spp. decrease while Enterococcus spp. and
Escherichia coli increase.33 34 Industrialisation has
Figure 1 Gut microbiota and the intrinsic and extrinsic factors that can affect its distribution and composition. A
number of host mechanisms participate in gut microbiota modulation, including gastric acid secretion, fluid,
anticommensal sIgA and antimicrobial peptide production, and gastrointestinal (GI) motility. Drugs that block acid
secretion and affect GI motility can indirectly alter the microbiota. Antibiotics, depending on spectrum and dosage, will
directly affect microbiota composition. Dietary modifications, including probiotic and fibre supplements, will also affect
microbiota composition. MMC, migrating motor complexes; H+ hydrogen ions; O2, partial oxygen tension; sIgA,
secretory immunoglobulin A; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory drug.
Recent advances in clinical practice
160 Gut 2013;62:159–176. doi:10.1136/gutjnl-2012-302167
group.bmj.com on April 25, 2016 - Published by http://gut.bmj.com/Downloaded from 
changed both our diet and microbiota as evidenced
by comparing the faecal microbiota of African rural
children with a polysaccharide-rich diet with Italian
city children on a high fat, high protein diet. African
children have a signiﬁcant enrichment in Bacter-
oidetes, especially Prevotella and Xylanibacter genera
known to contain genes for xylan hydrolysis35
(ﬁgure 2). Whole grain cereals,36 resistant starch37 38
and low residue diets profoundly alter the micro-
biota.39 Although there is evidence indicating that
obese individuals have an increase in Firmicutes and
a decrease in Bacteroidetes (a difference likely related
in part to different diets40), other studies failed to
support these observations.41 42 Many dietary
prebiotics including oligofructose,43 lactulose,44 45
lupin kernel,46 inulin-containing juices47 and arabi-
noxylan-oligosaccharides48 signiﬁcantly alter
human faecal microbiota. The concept of poorly
absorbed but fermentable oligo-, di- and mono-
saccharides and polyols (FODMAPs) includes many
substances which are substrates for bacterial
metabolism and may therefore alter the microbiota
but this has as yet not been studied.
Most high ﬁbre diets alter the microbiota and
accelerate transit. Accelerating transit using senna
increased the production of short chain fatty acids
(SCFAs) but reduced faecal methanogens, the
opposite to the effect of loperamide.49 Accelerating
transit with cisapride also increases production of
SCFAs, particularly propionic and butyric acids.50
Acetate, which predominates in the colonic
contents, is largely inhibitory. In contrast, propio-
nate and butyrate stimulate motility, activate
propulsive ileal motor patterns in humans51 and
ensure that bacteria are propelled from the ileum to
the colon. The normal microbiota also strongly
inﬂuence the mucosal immune system52 53 which is
underdeveloped in germ-free animals, who have
reduced T cells, immunoglobulin A producing B
cells and intraepithelial Tcells.52 54e56 Twin studies
suggest that the host genotype inﬂuences the gut
microbiota, although results remain conﬂicting
because of the inability to control for shared envi-
ronmental factors.40 57 One of the most important
genetic effects is mediated via the innate immune
response. Thus, mice lacking the bacterial sensing
receptor nucleotide-binding oligomerisation
domain-containing protein-2 showed signiﬁcantly
more Bacteroidetes as well as Firmicutes compared
with wild-type mice.58
Modulation of the microbiota induces visceral
hypersensitivity in mice, which is reduced by
Lactobacillus paracasei NCC2461 secreted prod-
ucts.59 Lactobacillus acidophilus NCFM and Lactoba-
cillus paracasei NCC2461 also modulate visceral
pain perception in rodents.60 61 Transient pertur-
bation of the microbiota with antimicrobials alters
brain-derived neurotrophic factor expression,
exploratory behaviour and colonisation of germ-
free mice suggesting that intestinal microbiota
impact is not limited to the gut and the immune
system, but may involve the central nervous
system.62 (Note: this last sentence appears run-on
but I can’t quite decipher how to ﬁx it.)
APPROACHES TO THE STUDY OF MICROBIOTA
Approaches to the study of microbiota and relative
advantages/pitfalls are reported in box 1. Culture-
based studies reveal that the gut microbiota is
a highly complex community (box 1).63 Although
culturing remains valuable for identifying func-
tional groups and for selective enumeration (eg, of
pathogens), new culture-independent approaches
provide more powerful and convenient methodolo-
gies for monitoring changes in the GI tract
community (table 1). Information on the diversity
of microbes that colonise the gut has expanded
rapidly over the past 15 years, based largely on the
analysis of the small subunit ribosomal RNA (16S
rRNA for Bacteria and Archaea, 18S rRNA for
Eukaryotes) gene sequences that can be obtained by
direct ampliﬁcation from nucleic acids extracted
from gut or stool samples.64 This information
provides the basis for a range of complimentary
techniques for enumerating gut bacteria, including
ﬁngerprinting methods such as denaturing gradient
gel electrophoresis65 and targeted methods such as
ﬂuorescent in situ hybridisation and quantitative
PCR. The arrival of new high-throughput
sequencing approaches and 16S rRNA-based
microarraying has further accelerated the supply of
data by allowing ampliﬁed 16S rRNA sequences to
be analysed indepth without the need for ‘classical’
cloning and sequencing methods.66 67 Although
culturing may bias against bacteria that are hard to
grow in the laboratory, PCR ampliﬁcation biases
against certain groups of gut bacteria. For example,
biﬁdobacterial 16S rRNA sequences are often
under-represented among ampliﬁed products,
although more reliably enumerated by 16S rRNA-
targeted ﬂuorescent in situ hybridisation detection
or quantitative PCR.37 While most molecular
enumeration methods target 16S rRNA, some are
based on more functionally relevant genes, for
Figure 2 Gut microbiota composition in African children living in rural areas with
a polysaccharide-rich diet when compared with Italian city children.35 (Reprinted with
permission from Proc Natl Acad Sci USA).
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example, involved in methanogenesis or butyrate
synthesis.
High-throughput DNA sequencing provides
completely new possibilities for ‘-omics’-based
analyses of the gut microbiota.19 Draft genomes of
cultured gut bacteria can now be produced rapidly
and at little cost.68 In addition, these methods can
be applied to DNA recovered from gut or stool
samples, and the analysis of the resulting complex
mixture of sequences is referred to as meta-
genomics.69 70 The ability to analyse multiple gene
sequences from large numbers of samples, comple-
mented with functional screening and character-
isation of randomly cloned DNA fragments from
the GI tract, is currently being exploited to uncover
changes in disease states including in inﬂammatory
bowel disease (IBD). A related technology, meta-
transcriptomics, uses high-throughput sequencing
or microarray analysis to examine RNA expressed
in GI tract samples, thus focusing on bacteria that
are transcriptionally active. Another potentially
powerful tool, metaproteomics, employs protein
separation and sequencing techniques to describe
the major proteins present in gut or stool
samples.71 72 These ‘meta-omics’ approaches rely in
primary sequencing and annotation data.73 74 Thus,
they rely heavily on the availability of genome
sequences and functional information from
cultured reference bacteria, which means there are
considerable beneﬁts from combining different
approaches to gut microbiota analysis. A ﬁnal
‘omics’ approach, metabonomics, is not linked
directly to genetic information of the microbes, but
examines the metabolite proﬁles resulting from
total microbial activity in the gut. Since many of
these metabolites exert biological effects (some
positive, some negative) on the host, such analysis
can provide a direct measure of the consequences of
microbial activity in the gut, although excluding
cell-mediated effects and direct identiﬁcation to
a target microbial species.
Breath testing has been used to detect SIBO in
IBS patients by non-invasively detecting hydrogen
producing bacteria or methane producing archaea
within the gut lumen. The breath test is based on
the concept that hydrogen gases are produced by
colonic bacterial fermentation in response to
ingestion of a test sugar. They rapidly diffuse into
the blood, are excreted by breath, and can be
collected and quantiﬁed.75 If SIBO exists, the
timing of this fermentation would be altered
but the criteria for abnormal tests lack validity
(ﬁgure 3).
DIFFERENCES IN THE MICROBIOTA IN FBD AND
THE LINK TO PATHOPHYSIOLOGY
There is little known about the small intestinal
microbiota as the small intestine is relatively inac-
cessible (summarised in table 2; box 2).75e85
Culture studies show considerably fewer bacteria
compared with the colon with a marked gradient
from duodenum to distal ileum. The bacteria are
typically Gram-positive aerobes proximally and
Gram-negative and Gram-positive anaerobes and
facultative anaerobes in the terminal ileum.
Culture-independent studies of the small intestinal
microbiota are in their infancy but suggest
complexity not appreciated by standard culture
techniques, including marked individual differ-
ences, ﬂuctuations over time (even within the same
day), age-related differences and several phylotypes
not previously identiﬁed.86e88 Moreover, a recent
paper indicated that the small intestinal microbiota
are driven by a rapid uptake and conversion of
available simple carbohydrates in which
Streptococcus spp. play an important role.89
The role of SIBO in the pathogenesis of IBS is
very controversial because the breath tests
employed to establish this role have not been vali-
dated.90 91 Even the validity of the ‘gold standard’,
jejunal cultures >105 cfu/ml with colonic-type
bacteria, has been challenged, largely because this
cut-off was established from samples following
surgical diversion.91 Studies in IBS patients showed
relatively few bacteria in the duodenum and prox-
imal jejunum and no obvious differences from
controls (table 2). Preliminary studies suggest that
more IBS patients have SIBO when a lower cut-off
of >103 cfu/ml is used but well-designed studies are
needed.82 85 Available molecular studies are not
adequately designed to establish whether SIBO is
involved in IBS but have signiﬁcant potential.
Several confounding factors, including acid
suppression by proton pump inhibitors (PPIs) and
altered motility, have been implicated in the studies
of SIBO and IBS.92e94 Some studies suggest that
PPI use might lead to symptomatic SIBO or at least
increased numbers of bacteria and that following
antibiotics they accelerate recurrence, but this
depends on the tests employed and criteria
applied.95 Although the link between SIBO and IBS
is largely based on breath testing, most positive
lactulose breath tests reﬂect rapid transit to the
caecum rather than true SIBO94 (ﬁgure 4). Other
factors such as antibiotics, probiotics and
Box 1 Approaches to the study of intestinal microbiota
< Breath tests are not validated to accurately detect small intestinal bacterial
overgrowth.
< Rapid molecular approaches have largely replaced cultural approaches for
enumeration of the dominant gastrointestinal (GI) tract microbiota.
< Cultural microbiology remains crucial for investigating microbial diversity and
for the selective isolation of representatives of key functional groups,
including pathogens.
< Culture-independent approaches to study the GI tract microbiota can answer
the questions:
– Which microbes are present in the GI tract? (16S rRNA gene-based
approaches)
– What microbial genes are present in the GI tract? (metagenomics)
– What are GI tract microbes doing? (metatranscriptomics, metaproteo-
mics, metabonomics/metabolomics).
< The possibilities of using high-throughput approaches and their depth of
analysis are increasing rapidly, but it is important they are applied with
careful reference to well-defined scientific questions.
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prebiotics, and other dietary items such as
FODMAPs could also inﬂuence microbiota in IBS
patients and result in a potentially spurious
association.
Earlier culture-based assessment of faecal micro-
biota obtained from patients with IBS demon-
strated decreased faecal lactobacilli and
biﬁdobacteria, and increased facultative bacteria
dominated by streptococci and Escherichia coli as
well as higher counts of anaerobic organisms such
as Clostridium.96 97 Studies using molecular-based
techniques reveal changes in faecal microbiota
composition in IBS versus controls (table 3). Inter-
estingly, a recent study demonstrated that faecal
microbiota of IBS patients could be grouped in
a cluster which was completely different from that
of healthy controls.114 Nonetheless, results to date
are inconsistent and sometimes contradictory
(table 3). This may reﬂect differences in molecular
techniques employed, the use of single samples that
are not linked to ﬂuctuating symptoms (especially
as studies suggest IBS faecal microbiomes are less
stable), and probably other factors such as diet and
phenotypic characterisation of patients. In addi-
tion, it should be realised that faecal samples do not
necessarily reﬂect other parts of the GI tract.
The ﬁnding that IBS can develop following
infective gastroenteritis prompted studies evaluating
the role of inﬂammation in IBS, but there are fewer
studies that focus on the associated changes in gut
microbiota, which might be just as signiﬁcant.
Infective gastroenteritis produces a profound deple-
tion of the commensal microbiota,118 whose
production of metabolites such as SCFAs and anti-
biotics normally inhibits pathogen colonisation, as
can be seen from the loss of colonisation resistance
after antibiotics.119 It is unclear just how completely
and over what time span recovery occurs.
Infective gastroenteritis is common, with an
incidence of 19/100 person years in the UK.120 A
third of episodes are viral (Norovirus/Rotavirus
being the commonest). The commonest bacterial
infections, Campylobacter and Salmonella, account
for 10% and 3%, respectively. Onset of new IBS
symptoms after a bout of infective gastroenteritis is
relatively common, reported by 6%e17% of IBS
patients,121 while a recent internet survey reported
18%,122 with around 40% beginning while travel-
ling. The clinical features of post-infectious-IBS
are predominantly those of IBS-diarrhoea
(IBS-D).123 124 A recent meta-analysis pooling 18
studies indicated a relative increased risk of devel-
oping IBS 1 year after bacterial gastroenteritis
(mostly Shigella, Campylobacter and Salmonella),
RR¼6.5 CI (2.6e15.4), an effect still apparent at
36 months, RR¼3.9 (3.0e5.0).125 Viral gastroenter-
itis, in keeping with the lesser tissue injury, shows
a reduced incidence of post-infectious-IBS
compared with bacterial infections126 127 in which
the strongest risk factors are bacterial toxicity,128
prolonged duration of diarrhoea,124 rectal
bleeding129 and fever.125 Acute enteritis is associated
with a prolonged increase in mucosal cytotoxic T
lymphocytes and increase in enteroendocrineTa
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cells.123 Other studies have shown the importance
of increased 5HT containing cells in IBS-D130 and
increased sensitivity in IBS-D with increased EC cell
counts,131 accelerated gut transit and visceral
hypersensitivity.132 These effects on gut physiology
will impact on the gut microbiota environment. An
early study of children with acute gastroenteritis
demonstrated alkalinisation of stool pH, likely due
to the decrease in bacterial metabolites (SCFAs) and
a fall in numbers of Bacteroides, Biﬁdobacterium,
Lactobacillus and Eubacterium.133 Conventional
enumeration of faecal bacteria showed a 10-fold fall
in anaerobes (Bacteroidaceae and Eubacterium), little
change in aerobes, but 109 cfu/g of pathogens.
Another study using conventional culture methods
showed a reversal of the normal anaerobe/aerobe
dominance during acute infection.134 More recent
human studies using modern culture-independent
methods tended to conﬁrm these ﬁndings.135 136
PCR-denaturing gradient gel electrophoresis
proﬁling of 16S rRNA genes showed a reduced
diversity, often associated with a dominant band
suggesting overgrowth of one subtype, which may
not always be the original pathogen. A recent clin-
ical trial of an oral rehydration solution containing
a prebiotic, amylase resistant starch in acute diar-
rhoea in India, including children aged 3 months to
5 years, used PCR primers directed at selected
bacteria, for example, Eubacterium spp. and Faecali-
bacterium prausnitzii, key bacteria involved in starch
fermentation. These studies showed a decline in
some anaerobes (Bacteroides spp., Eubacterium spp.
and Faecalibacterium prausnitzii) while other genera
including Biﬁdobacterium spp. were unchanged.135
This depletion of anaerobes could be due to accel-
eration of transit, which could lead to a loss of the
anaerobic niche. Since these are the key bacteria
involved in colonic salvage of unabsorbed carbohy-
drate,137 this may also contribute to the diarrhoea
phenotype by preventing fermentation to SCFAs,
which are known to stimulate colonic salt and
water absorption, both directly and by inducing
Figure 3 The lactulose hydrogen breath test (LHBT) predominantly measures small
intestinal transit rather than small intestinal bacterial overgrowth (SIBO) in irritable bowel
syndrome (IBS) patients. Upper schematic shows ingestion of test meal with subsequent
serial measurement of both H2 gas, resulting from fermentation of the lactulose by intestinal
bacteria, and Tc99 scanning in the caecum. This latter measurement detects when the test
meal has reached the caecum. The stylised drawing below shows a representative result
from an IBS patient with serial measurements over time. The Tc99 had already reached the
caecum in large quantities before the H2 PPM level has reached the threshold for an
abnormal test. This demonstrates that the increased H2 production results from fermentation
by colonic bacteria, not by abnormal bacteria small intestine (ie, SIBO).94
Table 2 Summary of studies culturing small bowel microbiome
Study Number of patients Sample type Microbiology results Comments
Drasar and Shiner76 13 Diarrhoea, all investigations
negative
Jejunal capsule No difference from controls;
no increased numbers of pathogens
or non-pathogens
Possible IBS but not defined as IBS
Rumessen et al77 60 Patients suspected of SIBO Proximal jejunal aspirate 15 With no predisposing cause
had no evidence of SIBO; of 23
with SIBO, 4 had no predisposing
cause
Groups poorly defined, 8 IBS identified
and all negative for SIBO; 22 cases
considered inconclusive
Corazza et al78 31 Chronic diarrhoea, no
predisposing cause
Proximal jejunal aspirate 10 Had SIBO ($106 cfu/ml or
colonic bacteria), 2 IBS, 8 other
multiple other diagnoses
IBS not defined, and total IBS not clear
Bardhan et al79 10 Controls; 4 irritable colon;
22 other
Endoscopic aspirates from
proximal jejunum
No positive cultures in irritable
colon
Positive cultures in 11 cases, many
postsurgical
Lewis et al80 23 With functional bowel
disorders
Duodenal endoscopic aspirate Mean control count 3.23102
cfu/ml, no anaerobes, no sterile
samples
No specific IBS, defined as functional
bowel disorders
Sullivan et al81 7 IBS; 20 controls Proximal jejunal biopsy using
Watson capsule
No differences, flora similar to
normal oropharyngeal flora
Colonic pathogen in 2 healthy subjects
Posserud et al82 162 IBS; 42 controls Proximal jejunal aspirate 4%$105 cfu, same as controls.
Subanalysis using $53103,
43% IBS vs 12% controls
No correlation with motor pattern in
IBS group
Kerckhoffs et al83 8 IBS; 9 controls Proximal jejunal aspirate No different number diagnosed
with SIBO using multiple definitions
No differences also using molecular-based
counts
Choung et al84 148 IBS; 542 ‘other
indications to test for SIBO’
Duodenal endoscopic aspirate 2% IBS >105 cfu/ml 10% in ‘other’
indications
Retrospective study 18% IBS
>0<105 cfu/ml
Pyleris et al85 85 IBS 150 non-IBS Duodenal endoscopic aspirate 37% IBS >103 cfu/ml 15.11% non-IBS All investigated because of UGI bleed
IBS, irritable bowel syndrome; SIBO, small intestinal bacterial overgrowth; UGI, upper gastrointestinal.
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increased expression of transporters.138e140 Previous
earlier studies in IBS-D suggest impaired SCFA
concentrations and production rates in ex vivo
incubation, which may also reﬂect reduced anaer-
obes.141
Another cause of depletion of anaerobes is broad-
spectrum antibiotics. There are no RCTs, but
epidemiological studies show an association
between antibiotic use and an increased risk of PI-
IBS.142 A study of children showed that 3 months
after Salmonella infection, vomiting, abdominal
pain and diarrhoea were reported by 9.5% of those
treated with antibiotics but only 2.9% of those
who received no antibiotics.142
Changes in the interaction between intestinal
microbiota and host factors (eg, age, diet, transit,
host genetic factors, antibiotics) could be important
for IBS pathophysiology. These factors, in turn, could
be related to changes in homeostatic pathways
including barrier function, neuromotor sensory
function and the brainegut axis.143 144 For example,
bidirectional signalling between the microbiota and
the epithelium regulates epithelial secretion of mucus
as well as other defence factors involved in regulating
the microbiota. Changes in these factors (eg, changes
in mucus layer and increased b-defensin-2 peptide)
have been detected in patients with IBS and func-
tional diarrhoea and suggest a microbiotaehost
immune system engagement.145 146 In line with this
concept, there is also recent demonstration that IBS
patients have increased colonic mucosal expression of
receptors recognising speciﬁc microbiota-related
substances (such as Toll-like receptor-4 which recog-
nises bacterial lipopolysaccharides)147 or increased
titres of circulating antibodies against components of
the indigenous microbiota (ie, antiﬂagellin anti-
bodies).148 Several studies demonstrated low-grade
activation of innate and adaptive mucosal immune
response in large subgroups of patients with
IBS.12 149 Increased activated mast cells, CD3+ve,
CD4+ve and CD8+ve T cells have been detected in
both postinfectious IBS and non-speciﬁc IBS.12 149
The relative importance of mast cells in this setting is
demonstrated by the abundance of this immune cell
type over other immunocytes and by increased
release from mucosal biopsies of histamine, tryptase
and prostaglandins.150 151 Mast cells were located in
closer vicinity to mucosal innervation and correlated
with the severity and frequency of abdominal pain in
patients with IBS.152 There are potential implications
of mucosal immune activation for sensorimotor
dysfunction of patients with IBS. Histamine and
tryptase released from mucosal biopsies of patients
with IBS evoked increased mesenteric sensory
afferent activation and induced visceral hyspersensi-
tivity via histamine-1 receptors and proteinase
activated-2 receptors when applied to recipient
rats.150 151 Intestinal microbiota may well be an
active participant in this scenario through stimula-
tion of the immune system,153 likely in the subgroup
of subjects showing increased epithelial permeability
which could154 expose the immune system to an
abnormal microbial antigenic load. Overall, the
results suggest that bacterialehost interactions may
be initiated by components of the microbiota that
can cross the mucus and adhere to epithelial cells,
inducing activation of the mucosal innate defence
system even in the absence of mucosal destruction.
The use of probiotics, particularly in animal
models, also demonstrates that their secreted
products or metabolites can modulate contractility
of intestinal smooth muscle and visceral
sensitivity.59e61 Moreover, application of probiotics
can recover neuromotor-sensory dysfunction in
IBS-like models.
Modulation of the brainegut axis is particularly
relevant in IBS because psychological comorbidity
is common. Some forms of psychological stress in
animal studies can induce shifts in the bacterial
composition of the gut that is accompanied by
systemic cytokine response and increased intestinal
permeability.155 The interplay may be bidirectional
as suggested by animal studies showing that the
microbiota can affect brain chemistry and behav-
iour.156 Nonetheless, for the time, the potential
relevance of brainemicrobiota interactions have yet
to be shown in humans in general and in FBD in
particular.
GI DISORDERS MIMICKING AND OVERLAPPING
WITH FBDS
Although celiac disease, IBD or diverticulitis can
coexist with IBS, an ‘IBS’ diagnosis in the presence
of an organic disease may be challenging.
Box 2 Relevance of studies showing changes in microbiota in irritable
bowel syndrome
< The relevance of small intestinal bacterial overgrowth in irritable bowel
syndrome (IBS) remains unclear due to methodological problems, influence of
confounding factors and large differences between studies.
< Heterogeneity of IBS and variation in methods used to study the faecal
microbiota have resulted in conflicting reports of differences from healthy
controls.
< The microbiome may contribute to IBS symptoms by altering gut neuromotor-
sensory function, barrier function and/or the brainegut axis.
Figure 4 Plot chart of currently available strategies for
modifying gut microbiota aiming to demonstrate the
relationship between the effectiveness and invasiveness/
safety of the proposed approach. FODMAP, fermentable
oligo-, di- and mono-saccharides and polyols; PPI, proton
pump inhibitor.
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Gluten causes coeliac disease in genetically
susceptible people and causes gut dysfunction in
mice and can generate IBS symptoms in the
absence of coeliac disease.157 Some patients with
IBS lack tissue transglutaminase antibodies or
histological markers of coeliac disease yet still
respond symptomatically to a gluten-free diet. This
entity is termed ‘non-coeliac gluten sensitivity ’ or
‘gluten sensitive IBS’.157e159 The underlying
mechanisms in humans remain unclear. Mouse
models indicate that gluten can induce activation
of innate immunity, increased small intestinal
permeability,160 neuro-muscular dysfunction159 and
dysbiosis161 in the absence of autoimmunity.
IBS-like symptoms are common in IBD patients
in long-standing remission, or are frequently
reported in patients before the diagnosis of
IBD.162 163 It is possible that IBS and IBD coexist
with a higher than expected frequency, or may exist
on a continuum, with IBS and IBD at different ends
of the inﬂammatory spectrum. A study investi-
gating IBS symptoms in IBD patients who were
thought to be in clinical remission demonstrated
high levels of calprotectin levels; this suggests that
in most cases IBS symptoms are the result of
undetected ongoing inﬂammation.164 Underlying
mechanistic links are lacking but it is tempting to
raise the hypothesis that the intestinal microbiota
may be a common factor in both diseases.165 In
fact, as with IBS (tables 2 and 3), faecal166e171 and
mucosal-associated dysbiosis167 172e178 has been
described IBD.
A high proportion of patients hospitalised with
acute diverticulitis continue to have persistent
symptoms that mimic IBS179 despite the absence of
complications.180 Some uncontrolled studies claim
beneﬁt from antibiotics and/or mesalazine
suggesting a role for the microbiota in this
syndrome.181
TREATMENT IMPLICATIONS: ANTIBIOTICS,
PROBIOTICS, PREBIOTICS AND SYNBIOTICS
As the microbiota may be disturbed in functional
GI disorders, a potential treatment approach is to
try to correct dysbiosis either by the administration
of an antibiotic or a preparation of ‘beneﬁcial’
bacteria (box 3).
Antibiotics
Despite evidence that previous antibiotic use may
be related to the development of IBS,182 183 and the
fact that antibiotic treatment may increase the
development of long-term digestive symptoms
after bacterial gastroenteritis,142 poorly absorbable
antibiotics might still have therapeutic potential in
this condition.184 Neomycin was the original
choice184 185 although interest is now focused on
a non-absorbed derivative of rifampicin called
rifaximin.186
There are three fully-published, double blind,
placebo controlled trials of rifaximin in FBD187e189
and the data suggest an improvement in symp-
toms, especially bloating and ﬂatulence for
approximately 10 weeks following treatment187 189Ta
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with a therapeutic advantage over placebo around
10%. The doses used in these and other studies vary
between 600 and 2400 mg daily for 7e14
days190e195 but there remain concerns about anti-
biotic resistance and possible Clostridium difﬁcile
infection although so far these issues have not
appeared to be a problem.196e200
Thus, a short course of gut-speciﬁc antibiotics
may have utility in some patients with IBS but we
need to know more about predictors of treatment
responsiveness, antibiotic resistance, the efﬁcacy
and safety of re-treatment schedules as well as the
optimal dosing regimen.201 202
Probiotics
Probiotics are live microorganisms which when
administered in adequate amounts confer a health
beneﬁt on the host203 with the most commonly
used being the lactobacilli and biﬁdobacteria.
Probiotics can be packaged in many formulations
containing just one organism or a mixture and have
a wide range of activities with evidence supporting
an effect on at least some of the putative patho-
physiological mechanisms implicated in IBS, such
as visceral hypersensitivity,59 60 204 205 GI
dysmotility,206e210 intestinal permeability,204 211 212
the intestinal microbiota213 214 and immune func-
tion215 although these effects can differ consider-
ably between one organism and another. Thus, just
because one organism is beneﬁcial, this does not
mean that related organisms will behave similarly.
For use in gastroenterology, it is important that
a preparation contains sufﬁcient quantities of
Box 3 Modulation of intestinal microbiota in functional bowel disorders
< A short course of a non-absorbable antibiotic such as rifaximin has been
shown to moderately improve the symptoms of irritable bowel syndrome
(IBS), particularly bloating and flatulence. Improvement persists after the
cessation of treatment but the exact duration of this effect remains uncertain.
< The majority of trials of probiotics in IBS show some degree of efficacy
although some of the early studies were of very poor quality.
< Prebiotics and synbiotics should theoretically have the potential in treating
functional gastrointestinal disorders but there are as yet no reliable data to
support this view.
Table 4 Placebo controlled clinical trials of single or mixed probiotic preparations in IBS
Organism n Outcome Reference
Studies in adult patients
S faecium 54 Y Global score Gade et al216
Lactobacillus acidophilus 18 Y Global score Halpern et al217
Lactobacillus plantarum 299V 60 Y Flatulence Nobaek et al218
L plantarum 299V 20 Y Pain, ‘all IBS symptoms’ Niedzielin et al219
L plantarum 299V 12 Negative Sen et al220
L plantarum MF1298 16 Deterioration of symptoms Ligaarden et al221
L ramnosus GG 25 Negative O’Sullivan et al240
L reuterii ATCC 55730 54 Negative Niv et al223
L salivarius UCC4331 75 Negative O’Mahony et al215
Bifidobacterium infantis 35624 75 Y Pain and composite score O’Mahony et al215
B infantis 35624 362 Y Pain and composite score Whorwell et al224
Bifidobacterium lactis DN-173-010 274 Y Digestive discomfort Guyonnet et al225
B lactis DN-173-010 34 Y Maximum distension & pain Agrawal et al208
Bifidobacterium bifidum MIMBb75 122 Y Global score Guglielmetti et al226
Bacillus coagulans GBI-30, 6086 52 Y Bowel movements Dolin222
Escherichia coli Nissle 1917 120 [ Treatment satisfaction Kruis et al227
VSL#3 (x8)* 25 Y Bloating Kim et al209
VSL#3 (x8)* 48 Y Flatulence Kim et al210
Medilac DS (x2)* 40 Y Pain Kim et al228
Mixture (x4)* 103 Y Global score Kajander et al229
Mixture (x4)* 86 Y Global score Kajander et al214
LAB4 (x4)* 52 Y Global score Williams et al230
Mixture (x4)* 106 Negative Drouault-Holowacz et al231
Mixture (x2)* 40 Y Pain Sinn et al232
ProSymbioFlor (x2)* 297 Y Global score Enck et al233
Cultura (x3)* 74 Negative Simre´n et al234
Cultura (x3)* 52 Negative Sondergaard et al235
Mixture (x4)* 70 Y Pain Hong et al236
Studies in paediatric patients
L ramnosus GG 50 Y Abdominal distension Bausserman and Michail237
L ramnosus GG 104 Y Pain Gawronska et al238
L ramnosus GG 141 Y Pain Francavilla et al212
VSL#3 (x8)* 59 Y Global score Guandalini et al239
*Number of organisms in a mixture.
n, number of randomised subjects.
IBS, irritable bowel syndrome; L ramnosus, Lactobacillus ramnosus; L reuterii, Lactobacillus reuterii; L salivarius, Lactobacillus salivarius; S faecium,
Streptococcus faecium.
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microbes which need to be acid and enzyme resis-
tant with good mucosal adherence also being an
advantage.
Table 4 lists the results of the fully
published placebo controlled probiotic trials to
date.208e210 212 214e240 Unfortunately, their designs
vary considerably;241e244 some of the older studies
are of poor quality, and few attempt to deﬁne the
mechanism of action or assess whether symptom-
atic improvement is accompanied by a change in
the microbiota. A recent systematic review reported
that studies of poorer quality tended to show larger
effects and published data indicate a publication
bias, with non-reporting of negative effects in small
trials.244 Around three-quarters of these studies
were positive, of which four were in children,
although different symptoms improved and the
therapeutic gain over placebo was generally
modest. Furthermore, it remains unclear which
organisms are most effective as, for instance, some
mainly reduce bloating and ﬂatulence,209 210 218
whereas others improve bowel frequency,222 and
some have a positive effect on global symptom
scores.214 215 224 226 229 230 233 In some of the better
quality trials biﬁdobacteria, such as Biﬁdobacterium
infantis 35624,215 224 241 Biﬁdobacterium lactis DN
173010208 225 and Biﬁdobacterium biﬁdum MIM-
Bb75,226 seem to be advantageous and in others
probiotic mixtures appear to be useful.214 229 233
In only one study was there symptom deteriora-
tion221 although some large, high quality trials
have been negative.221 231 234 235
Diet, fibre, prebiotics and synbiotics
There are few proper randomised, placebo controlled
trials of diet modiﬁcation because of the difﬁculty in
controlling for the placebo effect. One randomised
controlled trial showed bran aggravated symp-
toms;245 excluding bran should help, and many
patients believe this is true.246 A prebiotic is a product
that, on ingestion, stimulates the growth of beneﬁcial
bacteria already present in the host, which promotes
the health of the individual.247 248 A variety of
oligosaccharides serve this function and a synbiotic
is a combined prebiotic and probiotic. One of the
earliest prebiotics was lactulose, an unabsorbable
disaccharide laxative that increases the faecal
concentrations of Biﬁdobacterium spp.45 249 as does
inulin which, like lactulose, increases ﬂatulence47
and thus makes it unlikely it will help IBS patients.
To date, there has only been one double blind,
placebo controlled trial of a prebiotic in IBS which
used a trans-galactooligosaccharide mixture.250
Compared with placebo this prebiotic reduced
symptoms and stimulated the growth of biﬁdo-
bacteria but clearly more research is required on
dosing and the relative merits of other compounds.
With regard to synbiotics, there are some studies
but their design is not sufﬁciently robust to draw
any ﬁrm conclusions251e255 although the concept
of combining a prebiotic and probiotic is theoreti-
cally attractive. Thus, attempting to modify the
microbiota in patients with functional GI disorders
shows some promise. However, we need to know
how symptomatic improvement is achieved: is it
mirrored by a change in gut microbiota or is some
other mechanism involved?
CLINICAL GUIDANCE REGARDING MODULATION
OF INTESTINAL MICROBIOTA IN IBS
While the science regarding the role of microbiota
in FGIDs remains in its infancy, patients are
exposed to conﬂicting claims concerning the
symptomatic beneﬁt from modulating gut micro-
biota. This section aims to help clinicians give the
best advice, despite limited evidence (box 4).
Diet profoundly alters the microbiota. Reducing
intake of ﬁbre256 or FODMAPs257 is one of the
simplest and safest ways of altering gut microbiota,
which can lead to improvement in bloating and
diarrhoea, an effect which may last for years.258
However, so far the evidence to support widespread
use of FODMAP reduction in patients with IBS is
limited and comes mainly from one research group.
Systematic exclusion diets may also help258 but are
laborious; targeted exclusion of regularly consumed
suspects, such as dairy, wheat, fruit and vegetables,
may be more practical.
The safety of probiotics in IBS is acceptable but
some aggravate symptoms221 and so patients
should be warned of this possibility. At present, the
strongest evidence is for Biﬁdobacterium infantis
35624 at a dose of 13108 cfu/day taken for at least
4 weeks.224 It remains unclear who beneﬁts from
which variety of probiotic since there are many
incompletely answered questions surrounding this
therapeutic approach, including:
< Are single organisms better than mixtures or
vice versa?
< Do some mixtures of organisms contain strains
that are competitive or antagonistic without
additive effects?
< Can probiotic foods and drinks be administered
simultaneously?
Box 4 Diagnostic and therapeutic general recommendations
< There is currently no clinically useful way of identifying whether the
microbiota are disturbed in particular patients with irritable bowel syndrome
(IBS).
< Dietary evaluation and exclusion of possible sources of unabsorbable
carbohydrates including fermentable oligo-, di- and mono-saccharides and
polyols and excessive fibre could be beneficial in select patients.
< Probiotics have a reasonable evidence base and should be tried, for a period
of at least 1 month, at adequate doses before a judgement is made about the
response to treatment.
< The utility of testing for small intestinal bacterial overgrowth (SIBO) in the
setting of IBS remains an area of uncertainty.
< If SIBO is strongly suspected based on clinical presentation and testing is
being considered, using stringent criteria for the glucose breath test or jejunal
aspirate appear to be the best tests.
< Consideration should be given to discontinuing proton pump inhibitors in
those with SIBO.
< There is emerging evidence that non-absorbable antibiotics may have the
potential to reduce symptoms in some patients with IBS.
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< What are the best delivery systemsd
liquids or capsules?
< How can viability and bioavailability be
ensured?
< What are the optimal dosing regimens and their
duration?
< What is the frequency of host colonisation?
< Probiotics are not potent pharmacological
agents: what patient group should be targeted?
< Are there any groups of patients where probi-
otics might be contraindicated such as
newborns, immunocompromised or seriously ill
individuals?
< Are there any safety issues about some strains of
probiotics, for example, those of Escherichia coli?
< Should different probiotics be given to speciﬁc
subgroups of IBS patients?
< Which symptoms of IBS should be the main
target for therapy?
< What are the possible mechanisms behind
symptom improvement?
< How should doctors and patients be advised
about their administration?
The considerable acid suppression induced by
PPIs may alter upper gut microbiota and can
potentially induce IBS symptoms.92 Thus, it is
worth considering PPI discontinuation in selected
IBS patients on PPIs for unclear reasons, especially
if their symptoms started with PPI therapy.
The most direct way of altering gut microbiota is
to use broad-spectrum antibiotics. However, rapid
development of antibiotic resistance leads to
concerns about using antibiotics in such a ubiqui-
tous and chronic condition. Moreover, it is likely
that patients may require repeated courses of
therapy, as trial evidence suggests the beneﬁt
diminishes by 12 weeks.189 The best evidence is for
rifaximin 550 mg, thrice daily for 2 weeks.189 The
number-needed-to-treat was 11 which should be
compared with 4 for ‘placebo without deception,259
7 for alosetron,260 8 for linaclotide261 and 14 for
tegaserod.262
Although rifaximin appears to be well tolerated
and safe, given its relatively low potency its use
should be restricted to difﬁcult cases since its
widespread use could promote resistance, such as
rifampin-resistant strains of stapyholococci.196
Figure 4 provides a plot chart of currently available
strategies for modifying gut microbiota according
to the effectiveness and invasiveness of the
proposed approach, and general recommendations
appear in box 4.
CONCLUSIONS AND RECOMMENDATIONS FOR
FUTURE RESEARCH AND DEVELOPMENT
Although there is good evidence supporting the
concept that the intestinal microbiota is perturbed
in patients with FBD, we still lack data on the
mechanisms through which hostemicrobiota
interactions underlie pathophysiology and generate
symptoms; we need to overcome several boundaries
that hold back our knowledge in this ﬁeld.
The SIBO hypothesis in IBS remains a matter of
debate because the breath tests and the small bowel
culture techniques have not been validated. In addi-
tion, confounding factors, including the use of antibi-
otics or PPIs, have not been taken into account in
many studies. The wide heterogeneity of FBD and the
inter-individual variability of microbiota proﬁles
suggest that larger sample size studies (both in the
pathophysiology and therapeutic settings) are of key
importance in the future. Attention should be directed
to the assessment of correlations between microbiota
changes with patient’s symptoms. Whenever possible,
studies should be stratiﬁed by factors known or
assumed to affect intestinal microbiota (eg, age, diet,
enterotype) and designed to reduce potential
confounding factors (eg, antibiotics, probiotics, laxa-
tives, prokinetcs, PPI and mesalazine). Although faecal
samples are relatively easy to obtain, future work
should better characterise microbial populations at the
luminal and mucosal level which may differ substan-
tially from faecal microbiota. Hostemicrobiota inter-
actions are dynamic events and likely inﬂuenced by
several factors. This suggests that there is a need for
longitudinal studies assessing gut microbiota during
remission, and symptom ﬂare-ups, stress, infection or
following dietary manipulation and the use of probi-
otics, prebiotics and antibiotics. The effect of bowel
transit on microbiota proﬁles and correlation with
symptoms should also be assessed.
One important limitation of available studies is
their descriptive rather than mechanistic nature.
Accordingly, studies should be directed at clarifying
causeeeffect relationships between microbiota
changes and bowel dysfunction. In this way,
microbiota signatures can be developed to help
identify IBS biomarkers which might, in turn, offer
therapeutic targets. For example, the theory that
luminal bacteria may drive low-grade intestinal
immune activation should now be substantiated by
mechanistic and interventional studies. Data in
rodents suggest the existence of a bidirectional
interplay between the brain and gut microbiota.144
In addition, the existence of systemic immune
responses to microbial luminal antigens (anti-
ﬂagellin antibodies)148 provides initial evidence that
microbial homeostasis may be perturbed beyond
the GI tract. These aspects need to be further
explored to open new avenues of research in FBD.
Currently, there are promising results suggesting
that a subgroup of patients with FBD may respond
favourably to a short course of gut-speciﬁc antibi-
otics. However, most probiotic and antibiotic trials
are underpowered and suffer suboptimal design.
Bloating and ﬂatulence appear to be especially
responsive to non-absorbable antibiotics. In order
to safely direct these treatment options to the
appropriate patients, we need to know more about
predictors of treatment responsiveness, the risk of
development of antibiotic resistance, the efﬁcacy
and safety of re-treatment schedules, and the
optimal dosing regimen.201 202 Further studies
should also investigate the mechanism and site of
action of non-absorbable antibiotics since amelio-
ration of gas-related symptoms in patients occurred
also in patients with no evidence of SIBO.188
Probiotics seem to have a positive, albeit modest,
Recent advances in clinical practice
170 Gut 2013;62:159–176. doi:10.1136/gutjnl-2012-302167
group.bmj.com on April 25, 2016 - Published by http://gut.bmj.com/Downloaded from 
effect in both children and adults with FBD, espe-
cially IBS. However, head-to-head comparisons
between different probiotic products would be
useful and future trials need to be large scale, high-
quality and use valid end points. Trials should also
explore the mechanisms behind symptom
improvement.
Faecal transplantation is efﬁcacious in 145⁄166
(87%) patients with fulminant and refractory C
difﬁcile infection. This procedure has also been
proposed for the treatment of IBS but further
research is needed.263
In conclusion, a better deﬁnition of the role of
intestinal microbiota in the pathogenesis and
pathophysiology of FBD represents a challenge for
the future. Although promising, therapeutic impli-
cations will need to be better deﬁned in well-
conducted, large clinical trials. A strict cooperation
of experienced clinical researchers with microbial
ecologists should be considered an important factor
for the success of these future studies.
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